Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efruxifermin in Compensated Cirrhosis Due to NASH
NCT05039450Phase 2Completed
- Sponsor
- Akero Therapeutics
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
A Phase 2 trial of efruxifermin in Nonalcoholic steatohepatitis (NASH), sponsored by Akero Therapeutics. Started Jul 2021; status: completed.
02
Drugs
efruxifermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05039450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039450.